Key result
This review provides an overview of stroke and bleeding risk assessment in atrial fibrillation, focusing on the appropriate use of the CHADS2, CHA2DS2-VASc, and HAS-BLED risk stratification schemes.
Why the study?
How should stroke and bleeding risk be assessed in patients with atrial fibrillation to guide thromboprophylaxis?
How should stroke and bleeding risk be assessed in patients with atrial fibrillation to guide thromboprophylaxis?
This review highlights the importance of using structured risk scores like CHA2DS2-VASc and HAS-BLED to balance stroke and bleeding risks when deciding on thromboprophylaxis in atrial fibrillation.
No takes yet. Share an insight, caveat, or question.
Supports appropriate CHA2DS2-VASc and HAS-BLED use in AF thromboprophylaxis; leaves open need for updated prospective validation.
Gregory Y.H. Lip (2012) conducted a review in Atrial fibrillation. Stroke and bleeding risk assessment (CHADS2, CHA2DS2-VASc, HAS-BLED) was evaluated. This review provides an overview of stroke and bleeding risk assessment in atrial fibrillation, focusing on the appropriate use of the CHADS2, CHA2DS2-VASc, and HAS-BLED risk stratification schemes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: